Who Paid My Doc
Joseph McGowan
Infectious Disease Manhasset, NY
NPI 1689654840 CMS profile 75650
300 Community Dr, Dept Psych, Manhasset, NY 11030
General payments
$0
Research payments
$0
Ownership & investment interest
$0
The CMS Open Payments record contains no reported payments to Joseph McGowan of Manhasset, NY.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
Prescribing to Medicare patients
Part D · data year 2024 · 135 drugsPart D claims
6,670
Drug cost
$8,742,300
Branded share of claims
56%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 721 | $2,823,536 | |
| Tivicay Dolutegravir Sodium | Brand | 366 | $903,329 | |
| Rukobia Fostemsavir Tromethamine | Brand | 97 | $824,435 | |
| Descovy Emtricitabine/Tenofov Alafenam | Brand | 300 | $678,223 | |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | Brand | 129 | $646,075 | |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | Brand | 132 | $552,267 | |
| Dovato Dolutegravir Sodium/Lamivudine | Brand | 84 | $249,696 | |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | Brand | 44 | $207,474 | |
| Juluca Dolutegravir/Rilpivirine | Brand | 51 | $198,513 | |
| Sunlenca Lenacapavir Sodium | Brand | 11 | $195,724 |
The 10 drugs with the highest cost, of 135 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 32 billing codesPaid by Medicare
$26,986
Medicare patients
152
Services billed
337
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 51% | |
| Arthritis | 45% | |
| Diabetes | 39% | |
| Chronic kidney disease | 36% | |
| Heart failure | 28% | |
| Atrial fibrillation | 24% | |
| Depression | 24% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Vaccine for influenza for injection into muscle 90662 | Office | 21 | 21 | $1,708 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Other Infectious Disease in New York
Harish Moorjani
Infectious Disease · Briarcliff Manor, NY
Sorana Segal- Maurer
Infectious Disease · Flushing, NY
Sian Jones
Infectious Disease · New York, NY
Antonio Urbina
Infectious Disease · New York, NY
David Bekhor
Infectious Disease · New York, NY
Andre Brutus
Infectious Disease · Brooklyn, NY
Related records
Infectious Disease in New York
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.